Literature DB >> 31345389

Understanding financial toxicity in head and neck cancer survivors.

Leila J Mady1, Lingyun Lyu2, Maryanna S Owoc3, Shyamal D Peddada2, Teresa H Thomas4, Lindsay M Sabik5, Jonas T Johnson3, Marci L Nilsen6.   

Abstract

OBJECTIVES: (1) Describe financial toxicity (FT) in head and neck cancer (HNC) survivors and assess its association with personal/health characteristics and health-related quality of life (HRQOL); (2) examine financial coping mechanisms (savings/loans); (3) assess relationship between COmprehensive Score for financial Toxicity (COST) and Financial Distress Questionnaire (FDQ). PATIENTS AND METHODS: Cross-sectional survey from January - April 2018 of insured patients at a tertiary multidisciplinary HNC survivorship clinic who completed primary treatment for squamous cell carcinoma of the oral cavity, oropharynx, or larynx/hypopharynx.
RESULTS: Of 104 survivors, 30 (40.5%) demonstrated high FT. Patients with worse FT were more likely (1) not married (COST, 25.33 ± 1.87 vs. 30.61 ± 1.34, p = 0.008); (2) of lower education levels (COST, 26.12 ± 1.47 vs. 34.14 ± 1.47, p < 0.001); and (3) with larynx/hypopharynx primaries (COST, 22.86 ± 2.28 vs. 30.27 ± 1.50 vs. 32.72 ± 1.98, p = 0.005). Younger age (4.23, 95%CI 2.20 to 6.26, p < 0.001), lower earnings at diagnosis (1.17, 95%CI 0.76 to 1.58, p < 0.001), and loss in earnings (-1.80, 95%CI -2.43 to -1.16, p < 0.001) were associated with worse FT. COST was associated with HRQOL (0.08, p = 0.03). Most survivors (63/102, 60%) reported using savings and/or loans. Worse FT was associated with increased likelihood of using more mechanisms (COST, OR1.06, 95%CI 1.02 to 1.10, p = 0.004). Similar results were found with FDQ.
CONCLUSIONS: We found differences in FT by primary site, with worst FT in larynx/hypopharynx patients. This finding illuminates potential site-specific factors, e.g. workplace discrimination or inability to return to work, that may contribute to increased risk. FDQ correlates strongly with COST, encouraging further exploration as a clinically-meaningful screening tool.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cost sharing; Head and neck cancer; Health expenditures; Health services; Health-related quality of life; Multidisciplinary research; Out-of-pocket expenses; Patient reported outcomes; Survivorship; Treatment costs

Mesh:

Year:  2019        PMID: 31345389     DOI: 10.1016/j.oraloncology.2019.06.023

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  15 in total

1.  Identifying a cut-off score for the COST measure to indicate high financial toxicity and low quality of life among cancer patients.

Authors:  Marques S N Ng; Kai Chow Choi; Dorothy N S Chan; Cho Lee Wong; Weijie Xing; Pui Shan Ho; Cecilia Au; Mandy Chan; Man Tong; Wai Man Ling; Maggie Chan; Suzanne S S Mak; Raymond J Chan; Winnie K W So
Journal:  Support Care Cancer       Date:  2021-04-02       Impact factor: 3.603

2.  Surgical factors associated with patient-reported quality of life outcomes after free flap reconstruction of the oral cavity.

Authors:  Joaquin E Jimenez; Marci Lee Nilsen; William E Gooding; Jennifer L Anderson; Nayel I Khan; Leila J Mady; Tamara Wasserman-Wincko; Umamaheswar Duvvuri; Seungwon Kim; Robert L Ferris; Mario G Solari; Mark W Kubik; Jonas T Johnson; Shaum Sridharan
Journal:  Oral Oncol       Date:  2021-10-26       Impact factor: 5.337

3.  Out-of-Pocket Costs and Provider Payments in Cleft Lip and Palate Repair.

Authors:  Danielle H Rochlin; Lucy W Ma; Clifford C Sheckter; H Peter Lorenz
Journal:  Ann Plast Surg       Date:  2022-02-17       Impact factor: 1.763

4.  Validation of Korean Version of the COmprehensive Score for financial Toxicity (COST) Among Breast Cancer Survivors.

Authors:  Sungkeun Shim; Danbee Kang; Nayeon Kim; Gayeon Han; Jihyun Lim; Hyunsoo Kim; Jeonghyun Park; Mankyung Lee; Jeong Eon Lee; Seok Won Kim; Jonghan Yu; Byung Joo Chae; Jai Min Ryu; Seok Jin Nam; Se Kyung Lee; Juhee Cho
Journal:  Cancer Res Treat       Date:  2021-10-13       Impact factor: 5.036

5.  Prevision of multidisciplinary head and neck cancer survivorship care during the 2019 novel coronavirus pandemic.

Authors:  Marci Lee Nilsen; David A Clump; Mark Kubik; Karen Losego; Alyssa Mrozek; Elizabeth Pawlowicz; Debra Pickford; Shaum Sridharan; Katie Traylor; Tamara Wasserman-Wincko; Kelly Young; Dan Zandberg; Jonas T Johnson
Journal:  Head Neck       Date:  2020-05-18       Impact factor: 3.147

6.  Potential impact of the COVID-19 pandemic on financial toxicity in cancer survivors.

Authors:  Khalil Baddour; Lauren D Kudrick; Aakriti Neopaney; Lindsay M Sabik; Shyamal D Peddada; Marci L Nilsen; Jonas T Johnson; Robert L Ferris; Leila J Mady
Journal:  Head Neck       Date:  2020-04-28       Impact factor: 3.147

7.  Identifying missing links in the conceptualization of financial toxicity: a qualitative study.

Authors:  Sara L Lueckmann; Nadine Schumann; Christoph Kowalski; Matthias Richter
Journal:  Support Care Cancer       Date:  2021-10-30       Impact factor: 3.603

8.  The cost of cure: Examining objective and subjective financial toxicity in head and neck cancer survivors.

Authors:  Khalil Baddour; Mark Fadel; Meng Zhao; Michael Corcoran; Maryanna S Owoc; Teresa H Thomas; Lindsay M Sabik; Marci L Nilsen; Robert L Ferris; Leila J Mady
Journal:  Head Neck       Date:  2021-07-08       Impact factor: 3.821

9.  Flourishing in head and neck cancer survivors.

Authors:  Alexandria Harris; Jinhong Li; Karley Atchison; Christine Harrison; Daniel Hall; Tyler VanderWeele; Jonas T Johnson; Marci L Nilsen
Journal:  Cancer Med       Date:  2022-03-11       Impact factor: 4.711

10.  Women Who Are Young, Non-White, and with Lower Socioeconomic Status Report Higher Financial Toxicity up to 1 Year After Breast Cancer Surgery: A Mixed-Effects Regression Analysis.

Authors:  Mary C Politi; Renata W Yen; Glyn Elwyn; A James O'Malley; Catherine H Saunders; Danielle Schubbe; Rachel Forcino; Marie-Anne Durand
Journal:  Oncologist       Date:  2020-10-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.